Neurocognitive Disorders

Lewy body dementia psychosis drug pipeline

1 compound from 1 company is in active clinical development for lewy body dementia psychosis.

1Compound
1Company
0Phase 3+
1Upcoming readout
2Trials recruiting
  • Phase 2 1

Mechanisms: Small molecule (1)

Pipeline data compiled July 2026 · every fact sourced.

Upcoming readouts & recent results

  • February 2028AnticipatedRemlifanserinRegistry resultsNCT07029581

    ClinicalTrials.gov estimated primary completion of the Phase 2 Lewy body dementia psychosis efficacy study (NCT07029581, ACP-204-012): February 2028 (estimated study completion March 2028). ↗

See the full catalyst calendar →

Compounds in development (1)

CompoundCompanyPhaseStatusMechanism
RemlifanserinACADIA Pharmaceuticals Inc.Phase 2Recruiting5-HT2A Inverse agonist

Trials recruiting now (2)

2 drug-interventional lewy body dementia psychosis trials recruiting now, of 2 registered interventional trials. Browse all on ClinicalTrials.gov →

Frequently asked

How many drugs are in development for lewy body dementia psychosis?
1 compound from 1 company is in active clinical development for lewy body dementia psychosis.
What are the next lewy body dementia psychosis trial readouts?
Upcoming catalysts include Remlifanserin (February 2028).
How many clinical trials are recruiting for lewy body dementia psychosis?
2 drug-interventional lewy body dementia psychosis trials are currently recruiting participants, out of 2 registered interventional trials.